Comparison
DSIP vs. Epitalon
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
307297-39-8
Molecular weight
848.81 g/mol
390.35 g/mol
Half-life
0.1 h
0.3 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAla-Glu-Asp-GlyMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
4
of which in humans
1
1
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
1
1